Overview

Clinical Study to Assess the Pharmacokinetics, Safety, and Tolerability of ACT-129968 in Healthy Subjects

Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
To explore the pharmacokinetics (PK) of a single dose of two different formulations of ACT-129968, i.e., tablet versus capsule and to evaluate the safety and tolerability of a single dose of two different formulations of ACT-129968, i.e., tablet versus capsule.
Phase:
Phase 1
Details
Lead Sponsor:
Actelion
Idorsia Pharmaceuticals Ltd.